Red Queen Therapeutics is a Cambridge, MA–based clinical-stage biotechnology company applying a proprietary stapled lipopeptide platform to design and develop antiviral therapies for coronaviruses, influenzas and other enveloped viruses. Its platform works via fusion inhibition, a mechanism that acts on the virus itself rather than relying on the host immune system. Fusion inhibition blocks viral entry, which can prevent or slow host-cell infection and accelerate viral clearance, and a single fusion-inhibiting lipopeptide can work across variants and within viral families. The company’s stapled lipopeptide therapeutics are designed to be shelf-stable at room temperature and can be formulated for nasal spray, inhaler, or systemic injection. Red Queen also held a contract with BARDA for preclinical development of a pan-influenza therapeutic. The company raised funds to expand operations and advance development efforts.

Total raised

$55M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2024